This study evaluates the financial impacts of expanding global access to PD1/PD-L1 inhibitors as first-line monotherapy for patients aged 40–74 years with advanced unresectable non-small cell lung cancer (NSCLC), with wildtype EGFR and ≥50% of tumour cells with PD-L1 expression. Here, EGFR is linked to neoplasm.